Literature DB >> 21532612

Intrapleural delivery of mesenchymal stem cells: a novel potential treatment for pleural diseases.

Zhao-hui Qin1, Jie-ming Qu, Jin-fu Xu, Jing Zhang, Hanssa Summah, He-xi Ge Sai-Yin, Chun-mei Chen, Long Yu.   

Abstract

AIM: To develop a method to deliver mesenchymal stem cells (MSCs) into the pleural cavity for the treatment of pleural diseases.
METHODS: MSCs were isolated from rat bone marrow of rats and labeled with 4',6-diamidino-2-phenylindole dihydrochloride (DAPI) or green fluorescent protein (GFP) using a lentiviral vector. Eighteen Sprague-Dawley (SD) rats were inoculated intrapleurally with 1×10(6) MSCs-DAPI. The distribution of the fluorescent cells was observed using fluorescent microscopy for the following 30 d. Another 12 rats inoculated intrapleurally with 1×10(6) MSCs-GFP were observed for 14 d.
RESULTS: The isolated cells were typical MSC phenotypes and could differentiate into adipocytes, osteoblasts, and chondroblasts in vitro. Microscopic analysis revealed that the labeled cells adhered to the surface of the pleural cavity. The highest number of the labeled cells was found to be adhered to all specimens from the mediastinal pleura, but no labeled cells were detected in the lung parenchyma or other tissues/organs, such as the liver, kidney, spleen, and mesenterium. Incidentally, stomas were found in the mediastinal pleura. The recovered MSCs-GFP from the pleural cavity retained their ability to adhere and proliferate.
CONCLUSION: We have established a novel method for intrapleural delivery of MSCs. The distribution of intrapleurally delivered MSCs was found to be limited to the pleurae and the pleural cavity, thereby providing us with a new approach to further investigation of the therapeutic roles of MSCs in pleural diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21532612      PMCID: PMC4002516          DOI: 10.1038/aps.2011.22

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  16 in total

1.  Recurrent spontaneous pneumothorax.

Authors:  Aditya Gupta; Bela Patel; Khalid Almoosa; Brandy J McKelvy
Journal:  Cleve Clin J Med       Date:  2010-06       Impact factor: 2.321

2.  Distribution of diaphragmatic lymphatic stomata.

Authors:  D Negrini; S Mukenge; M Del Fabbro; C Gonano; G Miserocchi
Journal:  J Appl Physiol (1985)       Date:  1991-04

Review 3.  Stem cells and cell therapies in lung biology and lung diseases.

Authors:  Daniel J Weiss; Jay K Kolls; Luis A Ortiz; Angela Panoskaltsis-Mortari; Darwin J Prockop
Journal:  Proc Am Thorac Soc       Date:  2008-07-15

4.  Cytokines as the major mechanism of mesenchymal stem cell clinical activity: expanding the spectrum of cell therapy.

Authors:  Edwin M Horwitz; William R Prather
Journal:  Isr Med Assoc J       Date:  2009-04       Impact factor: 0.892

Review 5.  Anatomy of the pleura.

Authors:  N S Wang
Journal:  Clin Chest Med       Date:  1998-06       Impact factor: 2.878

6.  Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats.

Authors:  F Zhao; Y F Zhang; Y G Liu; J J Zhou; Z K Li; C G Wu; H W Qi
Journal:  Transplant Proc       Date:  2008-06       Impact factor: 1.066

7.  Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice.

Authors:  J Xu; J Qu; L Cao; Y Sai; C Chen; L He; L Yu
Journal:  J Pathol       Date:  2008-03       Impact factor: 7.996

Review 8.  Malignant pleural mesothelioma: medical treatment update.

Authors:  Daniel A Vorobiof; Keorapetse Mafafo
Journal:  Clin Lung Cancer       Date:  2009-03       Impact factor: 4.785

Review 9.  Recent advances in the diagnosis and management of malignant pleural effusions.

Authors:  John E Heffner; Jeffrey S Klein
Journal:  Mayo Clin Proc       Date:  2008-02       Impact factor: 7.616

Review 10.  Why are MSCs therapeutic? New data: new insight.

Authors:  A I Caplan
Journal:  J Pathol       Date:  2009-01       Impact factor: 7.996

View more
  3 in total

1.  Intrapleural delivery of MSCs attenuates acute lung injury by paracrine/endocrine mechanism.

Authors:  Zhao-hui Qin; Jin-fu Xu; Jie-ming Qu; Jing Zhang; Yin Sai; Chun-mei Chen; Lian Wu; Long Yu
Journal:  J Cell Mol Med       Date:  2012-11       Impact factor: 5.310

2.  Effects of neuritin on the differentiation of bone marrow‑derived mesenchymal stem cells into neuron‑like cells.

Authors:  Jingling Zhu; Pingping Meng; Qian Wang; Haiyan Wang; Jinli Zhang; Yuanyuan Li; Dongzheng Li; Xiaohua Tan; Lei Yang; Jin Huang
Journal:  Mol Med Rep       Date:  2017-07-14       Impact factor: 2.952

Review 3.  Mesenchymal stem/stromal cells: the therapeutic effects in animal models of acute pulmonary diseases.

Authors:  Sirous Sadeghian Chaleshtori; Mohammad Reza Mokhber Dezfouli; Massoumeh Jabbari Fakhr
Journal:  Respir Res       Date:  2020-05-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.